Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2002

View Archived Issues

Forest evaluates Lexapro on quality of life

Inhaled insulin is safe and effective in the management of type 1 and type 2 diabetes

Improved glucose control reported for AC-2993 in type 2 diabetes

Pramlintide effectively ameliorates excessive glucose fluctuations in diabetics

Phase III alvimopan trial in opioid-induced bowel dysfunction completes enrollment

Pilot study for Ixion's IxOC-2 oral oxalate therapy in hyperoxaluria patients

Esterom development terminated, new program for active component

NV-1020 completes phase I in colorectal cancer metastatic to the liver

Zadaxin enters phase II combination trial in malignant melanoma

J&J to file for two new indications for Topamax

SkyePharma and Meditech announce Solarase marketing agreement

Structure-activity studies at GSK leading to potent, selective MCH antagonists

Small-molecule HCV NS3 protease inhibitors discovered at Boehringer Ingelheim

Leo reports cyclic phosphonamide MMP inhibitors with antitumor activity

New class of Lp(a)-lowering agents presented last week in Barcelona

Combination of PPARgamma agonist and statin improves atherosclerotic lesion regression

Potential new treatment option for bladder overactivity: the NK2 antagonist M-274773

Onoact 50 launched in Japan

Novel 5-HT1B/5-HT1D antagonists in early development at AstraZeneca

FDA requests additional phase III trial of Cellegesic

Dalbavancin gives better response rates than standard of care in SSTIs

AstraZeneca researchers identify new 5-HT1B/5-HT1D agonists with potential in migraine

New cholesterol synthesis inhibitors covered by Mochida patent

Novel PDE5 inhibitors in the Eisai pipeline

Antibacterial compounds prepared and tested at GSK

Novel CCR1 antagonists and their use in asthma and other disorders

Insmed discontinues INS-1 development